Aeolus Pharmaceuticals Inc. recently reported that its AEOL 20415 protected the lungs in a mouse model of cystic fibrosis, increasing further speculation that the drug could be used as both a treatment for cystic fibrosis, as well as antibiotic-resistant bacteria.
"This study confirms previous in-vitro studies indicating that AEOL 20415 is unique because it augments the body's natural host defense system for fighting bacterial infection while limiting inflammation," Brian Day, vice chair of research at National Jewish Health, said in a press release.
Day conducted the study.
"Currently available anti-inflammatory drugs work by suppressing the immune system, which can be counterproductive during active infection," he said.
John McManus, CEO of Aeolus Pharmaceuticals, said the company is looking forward to sharing the data with potential collaborators in industry and the government as a continuing effort to address unmet medical needs.
"The combination of anti-microbial and anti-inflammatory action of AEOL 20415 makes it particularly effective in addressing antibiotic-resistant infectious disease threats, as well traditional indications like cystic fibrosis," McManus said.
